Duranti Leonardo, Pardolesi Alessandro, Bertolaccini Luca, Tavecchio Luca, Scanagatta Paolo, Rolli Luigi, Pastorino Ugo
Thoracic Surgery Unit, National Cancer Institute, Milan, Italy.
Thoracic Surgery, Maggiore Teaching Hospital, Bologna, Italy.
J Thorac Dis. 2019 Mar;11(3):1022-1030. doi: 10.21037/jtd.2019.02.61.
The extra-pleural pneumonectomy (EPP) is a standardised surgical procedure born for pleural tuberculosis and later used in pleural cancer treatment, especially in malignant pleural mesothelioma (MPM). This systematic review aimed to focus on the actual overall EPP role in surgical oncology. The literature search was performed from January 1985 to January 2018 In PubMed, Embase, and Cochrane according to PRISMA protocol. The search was restricted to publications in English with the research words "extrapleural pneumonectomy", "malignant pleural mesothelioma", "pleural malignancies". The results were then filtered focusing only on papers with series of patients treated with EPP, for mesothelioma and non-mesothelioma malignancies. The search was restricted to publications in English. We found a 5-year overall survival (OS) ranging from 0 to 78%. The peri-operative mortality and morbidity ranged from 0 to 11.8% and 0 to 82.6%, respectively. The most represented and described post-operative complications reported were ARDS, pericardial tamponade, cardiac herniation, pulmonary embolism, respiratory infections, respiratory failure, atrial arrhythmia, myocardial infarction. In referral centres and selected patients, EPP is a cytoreductive or radical surgical treatment in extended pleural malignancies. Prospective studies are needed to standardise the timing of the procedure in a multimodality treatment program, according to the oncological and functional indications, to keep an acceptable complications rate and post-operative quality of life status.
胸膜外全肺切除术(EPP)是一种标准化的外科手术,最初用于治疗胸膜结核,后来用于胸膜癌治疗,尤其是恶性胸膜间皮瘤(MPM)。本系统评价旨在聚焦EPP在外科肿瘤学中的实际整体作用。根据PRISMA方案,于1985年1月至2018年1月在PubMed、Embase和Cochrane数据库中进行文献检索。检索限于英文出版物,检索词为“胸膜外全肺切除术”“恶性胸膜间皮瘤”“胸膜恶性肿瘤”。然后仅筛选关注接受EPP治疗的间皮瘤和非间皮瘤恶性肿瘤患者系列的论文。检索限于英文出版物。我们发现5年总生存率(OS)为0%至78%。围手术期死亡率和发病率分别为0%至11.8%和0%至82.6%。报告最多且描述的术后并发症有急性呼吸窘迫综合征(ARDS)、心包填塞、心脏疝、肺栓塞、呼吸道感染、呼吸衰竭、房性心律失常、心肌梗死。在转诊中心和选定患者中,EPP是一种用于广泛性胸膜恶性肿瘤的减瘤或根治性手术治疗。需要进行前瞻性研究,以便根据肿瘤学和功能指征,在多模式治疗方案中规范该手术的时机,以保持可接受的并发症发生率和术后生活质量状态。